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INTRODUCTION:  
Ocular surface squamous neoplasia was first described 
by Lee and Hirst
1. 
In 1995 as an umbrella term that 
denotes spectrum of neoplasia originating from 
squamous epithelium ranging from dysplasia to 
invasive squamous cell carcinoma. OSSN incidence is 
increasing throughout the world with higher frequency 
in the equatorial region. Variety of etiological factors 
like HIV, HPV infections, exposure to UV rays are 
attributed.
2
 Mitomycin C had been used alone or as 
adjuvant therapy after surgical excision in various 
studies.
3 
Aim: To study the effect of Mitomycin C on recurrence 
of OSSN after surgical excision. 
MATERIALS AND METHODS:  
This is a Randomized prospective interventional study 
conducted at Sarojini Devi Eye Hospital, Hyderabad 
between October 2012 to September 2014 in the 
department of Oculoplasty. 54 patients 36 males 18 
females who were clinically diagnosed as OSSN by slit 
lamp examination by an experienced Ophthalmologist 
were included in the study. Cases who underwent 
treatment were excluded from study. 54 cases were 
randomly divided into two groups of 18 males and 9 
females. Informed consent taken after explaining the 
procedure in the patient’s own language. Routine 
surgical profile was performed. All 54 cases were 
subjected to surgical excision of OSSN under topical 
anaesthesia of 4% Lignocaine drops with Local 
infiltration of 2% Lignocaine around the tumour. OSSN 
was excised using Crescent blade of small incision 
cataract surgery with 3mm of normal conjunctival 
margin
4
. Cryo applied to bare area with Freeze-thaw-
Freeze technique for thirty seconds with 5mm 
cryoprobe.
5,6 
Group A were followed up every month for recurrence 
up to 2 years. Group B were given topical Mitomycin C 
drops 0.04% one drop four times daily for 4 days a 
week with 3 days off. This constitutes one cycle and 
patients were asked to use drops for four cycles. These 
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patients were also followed up every month for a period 
of 2 years. 
RESULTS:  
In Group A, 4 cases (14.8%) had recurrence within one 
year. All 4 were males. Group B had no recurrence even 
after two years. 
 
Figure 1: Showing squamous cell carcinoma. 
DISCUSSION:  
Studies conducted elsewhere in the world showed 
similar results. H C Russell et al used MitomycinC 
alone in 58 cases of OSSN. They reported nil 
recurrence in Conjunctiva cornea intraepithelial 
neoplasia.  Recurrence occurred in 6.8% cases that had 
Invasive squamous cell carcinoma.
7 
A Gupta et al used MMC in 73 cases of OSSN which 
had a mix of primary tumors and recurrence tumors. 
There was no recurrence in primary tumors.
8 
No recurrence was reported by C Chen et al who had 
used MMC drops as adjuvant after surgical excision of 
OSSN in 27 cases.
9 
 
Figure 2: Clinical picture of OSSN 
CONCLUSION:  
It is concluded that use of MMC drops as adjuvants 
after surgical excision is effective in preventing 
recurrence.
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